Step 1 topics → Reproductive → HPV and Cervical Dysplasia (CIN)

HPV and Cervical Dysplasia (CIN)

USMLE Step 1 trap: Confuses which HPV oncoprotein targets p53 vs Rb. HPV E6 inactivates p53 (targeting it for ubiquitin-mediated degradation) and E7 inactivates Rb.

HPV and cervical dysplasia is one of the highest-yield reproductive pathology topics on USMLE Step 1. The exam tests it at every level — from the molecular mechanism of oncogenesis (E6/E7 proteins) to the histologic grading of CIN to screening management decisions. You need to be comfortable moving between these layers quickly, because a single vignette might require you to identify koilocytes, apply the correct CIN grade, and then choose an appropriate screening interval. The concept is deceptively learnable, which is exactly why so many students pick up wrong models early and carry them into the exam.

The two biggest pitfalls are swapping E6 and E7 targets (a very common reversal that the exam is specifically designed to catch) and misunderstanding what CIN grading actually measures. Students often conflate CIN grade with invasion depth — a completely different concept. CIN by definition has NO stromal invasion; it is entirely an intraepithelial process. The grade tells you what fraction of the epithelial thickness is replaced by dysplastic cells, not how deep those cells have gone into underlying tissue. Once invasion occurs, you're no longer talking about CIN — you're talking about invasive carcinoma.

USMLE Step 1 also likes to test screening protocols, particularly where age thresholds shift the recommendation. Many students memorize 'Pap every 3 years' and apply it to all women up to age 65, missing the fact that co-testing becomes an option at 30. The vaccine coverage question is another trap — knowing that the 9-valent vaccine covers specific strains (not all HPV) and includes both high-risk and low-risk types is fair game. Lock down the molecular mechanism, the grading system, and the screening rules, and this topic becomes reliable points.

From real student decks
51%have cards covering this topic
32%have mature cards

Common misconceptions

Common mistake
Wrong: HPV E6 inactivates Rb and E7 inactivates p53.
Right: HPV E6 inactivates p53 (targeting it for ubiquitin-mediated degradation) and E7 inactivates Rb.
Students reverse E6 and E7 targets constantly — it's the single most tested factual trap in this topic. The correct model: E6 binds p53 and tags it for ubiquitin-mediated proteasomal degradation, eliminating the cell's ability to arrest the cycle or trigger apoptosis after DNA damage. E7 binds and inactivates Rb, releasing E2F transcription factors and driving unchecked cell cycle progression into S phase. A mnemonic that helps: E6 knocks out p53 (both have one syllable, or think '6 letters in cancer' targeting the guardian of the genome), E7 targets Rb.
Common mistake
Wrong: CIN grade reflects the depth of stromal invasion by dysplastic cells.
Right: CIN grade reflects the proportion of epithelial thickness replaced by dysplastic cells (CIN1 = lower 1/3, CIN2 = lower 2/3, CIN3 = full thickness), with no stromal invasion in any CIN.
CIN grading measures the fraction of epithelial thickness occupied by dysplastic (immature, high nuclear-to-cytoplasmic ratio) cells — CIN1 is the lower third, CIN2 is the lower two-thirds, CIN3 is full thickness. Critically, none of these grades involve stromal invasion; the moment dysplastic cells breach the basement membrane, the diagnosis becomes invasive carcinoma. Confusing CIN grade with invasion depth leads to fundamental errors in both pathology questions and management questions on USMLE Step 1.
Common mistake
Wrong: The HPV vaccine protects against all HPV strains, including low-risk types causing condyloma.
Right: The 9-valent vaccine covers high-risk strains 16, 18, 31, 33, 45, 52, 58 and low-risk strains 6 and 11 (which cause condyloma), but does not cover all HPV strains.
The HPV vaccine does not cover all HPV strains — it covers a defined set. The 9-valent Gardasil covers high-risk types 16, 18, 31, 33, 45, 52, and 58 (responsible for the vast majority of cervical cancers) plus low-risk types 6 and 11 (which cause condyloma acuminata). Students who think it covers 'all HPV' will get tripped up on questions asking whether vaccinated women still need screening — they absolutely do, because the vaccine doesn't cover every oncogenic strain.
Common mistake
Wrong: Pap smear alone is recommended every 3 years for all women aged 21–65.
Right: Pap smear alone every 3 years is recommended for ages 21–29; for ages 30–65, co-testing (Pap + HPV) every 5 years or Pap alone every 3 years is acceptable.
The age-based split matters: for women aged 21–29, Pap smear alone every 3 years is recommended (HPV co-testing is not used in this group because transient HPV infections are common and co-testing would generate too many false positives). For women aged 30–65, either co-testing (Pap + HPV) every 5 years or Pap alone every 3 years is acceptable. Applying the 21–29 protocol to all women through age 65 ignores the evidence-based shift in strategy at age 30 — a distinction USMLE Step 1 tests directly.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the molecular mechanism of high-risk HPV oncogenesis: specifically which oncoprotein (E6 vs E7) targets p53 and which targets Rb, and what happens to each tumor suppressor as a result.
  2. Know how to grade CIN based on the proportion of the epithelial thickness replaced by dysplastic cells, and recognize that no CIN grade involves stromal invasion.
  3. Know the cervical cancer screening intervals by age group (21–29 vs 30–65), including when co-testing with HPV is appropriate and when it is not, and know the HPV vaccine schedule and which strains it covers.

Can you avoid these mistakes?

A biopsy shows dysplastic cells replacing the lower two-thirds of the cervical epithelium with intact basement membrane. What is the CIN grade, and does this represent invasive carcinoma? What would need to change histologically to upgrade this to invasive cancer?
High-risk HPV integrates into the host genome and produces E6 and E7 proteins. Which protein inactivates p53, by what mechanism, and what is the downstream consequence for the cell cycle? Which protein targets Rb, and what does Rb normally do that is now lost?
A 32-year-old woman with no prior abnormal Pap smears and a negative HPV test asks how long she can wait before her next cervical cancer screening. What do you tell her, and why does her age change the recommendation compared to a 25-year-old?
A patient received the 9-valent HPV vaccine series at age 13. She now presents with a cauliflower-like genital lesion that biopsies as condyloma acuminata. Is this consistent or inconsistent with having been vaccinated? Which HPV types cause condyloma, and are they covered by the vaccine?

Related topics

Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Complete Androgen Insensitivity Syndrome (CAIS)

See how your Anki deck covers this topic.

Upload your deck for a free audit →